{
    "nctId": "NCT00893035",
    "briefTitle": "Evaluation of an Apoptotic Test for Predicting Late Toxicities After Radiotherapy in Breast and Prostate Cancer Patients",
    "officialTitle": "Multicenter Prospective Evaluation of a Predictive Test of Late Toxicities After Radiotherapy by the Rate of Radiation Induced CD8 T-Lymphocyte Apoptosis: Application to Breast and Prostate Cancers.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Prostate Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 885,
    "primaryOutcomeMeasure": "Late complications",
    "eligibilityCriteria": "Inclusion Criteria for prostate cancer patients:\n\n* localised prostate cancer, histologically proven\n* Absence of metastases (M0) : normal bone scintigraphy\n* Absence of radiological lymph node invasion (N0).\n* Clinical Stage : T \u2265 T1c-T2a and \\< T3b Or T1b or c with PSA \u2264 10 ng/ml . Or T1b or c with Gleason \u2265 6\n* PSA \\< 30 ng/ml.\n* Signs and symptoms according to NCI/CTC v3.0 \\< grade 2\n* ECOG Performance status \u2264 1\n* Absence of hip prothesis\n* Absence de endopenian stent\n* Patient aged \\> 18 and \\< 80\n* Patient affiliated with social security\n* Written informed consent, dated and signed\n\nExclusion Criteria for prostate cancer patients:\n\n* Antecedents of invasive cancer (unless if treated more than 5 years ago without evolution) except basocellular carcinoma\n* positive biopsy of seminal vesicle\n* PSA \u2265 30 ng/ml for two successive dosages\n* Previous pelvic irradiation\n* Previous radical prostatectomy for cancer\n* Patients with another systemic disease (cardiovascular, renal, hepatic, pulmonary embolism, etc.) non stabilised or generalised sclerodermitis.\n* Patients known to be HIV seropositive (no specific test is necessary for defining eligibility)\n* Known homozygote ATM (Ataxy telangiectasy) mutation\n* Impossibility for a correct follow up (for social family or geographical reasons)\n* Patients incapable of providing consent, protected majors, vulnerable persons\n* Patients participating in other clinical trials\n\nInclusion Criteria for breast cancer patients:\n\n* Breast Conservative surgery\n* Non metastatic, M0\n* negative surgical margins\n* T1, T2; negative sentinel lymph node N0, N1 or N2.\n* Signs and symptoms according to NCI/CTC v3.0 \\< grade 2\n* Patient aged over 18 years and less than 60 or more than 60 with an indication for boost irradiation.\n* Patient affiliated with social security\n* Written informed consent, dated and signed\n\nExclusion Criteria for breast cancer patients:\n\n* Metastatic patients\n* Bilateral breast cancer (concomitant or previous) except in situ\n* T4 or N3 or treated by mastectomy\n* Patients with chemotherapy or neoadjuvant hormonotherapy\n* Patients with a previous other cancer within the last 5 years EXCEPT basocellular carcinoma of the skin or in situ cancer of the uterus.\n* Patients with another systemic disease (cardiovascular, renal, hepatic, pulmonary embolism, etc.) non stabilised or generalised sclerodermia.\n* Pregnant or breast feeding women\n* Patients known to be HIV seropositive (no specific test is necessary for defining eligibility)\n* Known homozygote ATM (Ataxy telangiectasy) mutation\n* Impossibility for a correct follow up (for social family or geographical reasons)\n* Patients incapable of providing consent, protected majors, vulnerable persons\n* Patients participating in other clinical trials",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}